💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sotatercept

CHEMBL1743073 Phase 4 अनुमोदित Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Sotatercept is a fusion protein consisting of the extracellular domain of activin receptor type IIA (ActRIIA) fused to the Fc region of human IgG1, acting as a ligand trap for TGF-beta superfamily members including activin A, to treat pulmonary arterial hypertension. By sequestering hyperactivated TGF-beta/activin signaling, it counteracts pulmonary vascular smooth muscle cell proliferation and vascular remodeling in PAH. Clinical trials demonstrated significant improvements in exercise capacity and hemodynamics in PAH patients.

चिकित्सीय क्षेत्र

उच्च रक्तचाप ऑस्टियोपोरोसिस मूत्राशय कैंसर ल्यूकेमिया

क्रिया का तंत्र

Engineered protein combining domains from two different proteins to achieve enhanced therapeutic activity, often linking a receptor-binding domain with an immunoglobulin Fc region for extended half-life.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Engineered protein combining domains from two different proteins to achieve enhanced therapeutic activity, often linking a receptor-binding domain with an immunoglobulin Fc region for extended half-life.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

Sotatercept is a fusion protein consisting of the extracellular domain of activin receptor type IIA (ActRIIA) fused to the Fc region of human IgG1, acting as a ligand trap for TGF-beta superfamily members including activin A, to treat pulmonary arterial hypertension. By sequestering hyperactivated TGF-beta/activin signaling, it counteracts pulmonary vascular smooth muscle cell proliferation and vascular remodeling in PAH. Clinical trials demonstrated significant improvements in exercise capacity and hemodynamics in PAH patients.

Engineered protein combining domains from two different proteins to achieve enhanced therapeutic activity, often linking a receptor-binding domain with an immunoglobulin Fc region for extended half-life.

Yes, Sotatercept is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1743073. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.